|Videos|November 17, 2022

Currently Available Treatment Options for Relapsed/Refractory Multiple Myeloma

Author(s)Rafael Fonseca, MD, Amrita Y. Krishnan, MD, Caitlin Costello, MD

Dr Krina Patel presents the case of a relatively young patient with relapsed multiple myeloma, and Dr Caitlin Costello shares her approaches to treating relapsed/refractory multiple myeloma in her clinical practice.

Episodes in this series

The panel sits behind a desk, smiling at the camera.

EP. 1 Induction Regimen Options for Patients with Transplant-Eligible NDMM

The panel sits behind a desk, smiling at the camera.

EP. 2 Selecting a Treatment Regimen for Patients with Transplant-Eligible NDMM

The panel sits behind a desk, smiling at the camera.

EP. 3 Measuring Treatment Response in Transplant-Eligible NDMM

The panel sits behind a desk, smiling at the camera.

EP. 4 First-Line Treatment Options in Transplant-Ineligible NDMM

The panel sits behind a desk, smiling at the camera.

EP. 5 Treatment Regimens for Frail Patients with Transplant-Ineligible NDMM

The panel sits behind a desk, smiling at the camera.

EP. 6 Goals and Duration of Treatment for Elderly Patients with Transplant-Ineligible NDMM

The panel sits behind a desk, smiling at the camera.

EP. 7 Currently Available Treatment Options for Relapsed/Refractory Multiple Myeloma

The panel sits behind a desk, smiling at the camera.

EP. 8 Novel Bispecific Agents in the Treatment of Multiple Myeloma

The panel sits behind a desk, smiling at the camera.

EP. 9 CAR T-Cell Therapy in Multiple Myeloma Treatment

The panel sits behind a desk, smiling at the camera.

EP. 10 Unmet Needs and Future Directions in Multiple Myeloma Treatment

Recap: A Review of the Treatment Landscape in Multiple Myeloma

EP. 11 Recap: A Review of the Treatment Landscape in Multiple Myeloma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

October 29th, 2026

Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

$FDA Receives BLA for Etentamig in Relapsed/Refractory Multiple Myeloma$

October 27th, 2026

FDA Receives BLA for Etentamig in Relapsed/Refractory Multiple Myeloma

Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.

The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.

October 27th, 2026

Elranatamab Improves PFS vs Standard Regimens in R/R Multiple Myeloma

The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.

In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.

October 24th, 2026

Belantamab Mafodotin Combo Yields High MRD Negativity in NDMM

In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.

Trending on CancerNetwork

Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer

CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial

Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma

Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy

Recapping GI Cancer at ESMO 2026: Standout Data From Phase 1 to Phase 3